
Opinion|Videos|July 3, 2024
Gene Therapy for Treatment of Duchenne Muscular Dystrophy
Author(s)Emma Ciafaloni, MD
Focusing on gene therapy and exon skipping medications, an expert on Duchenne muscular dystrophy discusses current and emerging treatment options.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Provide an overview of delandistrogene moxeparvovec, micro-dystrophin gene therapy, that received accelerated approval for Duchenne muscular dystrophy (DMD) in 2023.
- Discuss ongoing studies for fordadistrogene movaparvovec gene therapy and other exon skipping therapies.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding VTX3232’s Effects on Patients with Early-Stage Parkinson Disease
2
FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease
3
Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited
4
Ocrelizumab’s Encouraging Treatment Effects Across Conception Delivery and Breastfeeding
5








































